Seal Rock Therapeutics Joins The Michael J. Fox Foundation's LITE Program to Advance New Therapies Targeting LRRK2 for Parkinson's Disease

SEATTLE, Aug. 13, 2025 ~ Seal Rock Therapeutics, Inc. has recently made a significant move in the field of Parkinson's disease research by joining The Michael J. Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. This program aims to support the development of new therapies targeting LRRK2, a protein associated with Parkinson's disease.

Seal Rock Therapeutics is a clinical stage company that focuses on improving the lives of individuals living with liver, brain, or neuromuscular diseases who have limited treatment options. Their brain-penetrant LRRK2/ASK1 signaling complex (LASC) inhibitors have shown promising results in preclinical studies, demonstrating powerful neuroprotective effects.

The company's LASC inhibitors are first-in-class oral molecules that act by simultaneously blocking both LRRK2 and ASK1, another protein involved in Parkinson's disease. This dual inhibition has proven to be more effective than targeting either protein alone and has also eliminated the kidney and lung toxicity commonly seen with other LRRK2 inhibitors.

More on Rezul News

• Integris Composites Joins Pacific Future Forum in Tokyo
• Titan Pressure Washing Educates Stuart Florida Neighborhoods on Lichen, Algae, and Moss Cleanup
• BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
• DFW Hard Money Rebrands as PBR Capital Partners, Signaling a Broader, Growing CRE Finance Platform
• IRL Investigations Combines Decades of Experience with Modern Digital Expertise

Neil McDonnell, CEO of Seal Rock Therapeutics, expressed his excitement about joining MJFF's LITE program and being part of a consortium of academic and industry leaders who recognize the potential of LRRK2 inhibition for Parkinson's disease. He also praised MJFF for their recognition of the need for collective action and their support in pursuing this promising target.

Through their participation in the LITE initiative, Seal Rock Therapeutics hopes to gain a better understanding of their LASC inhibitors through research conducted by top labs in the field. McDonnell believes that this collaboration will not only advance their own program but also contribute to a better understanding of how ASK1 and LRRK2 play a role in Parkinson's disease.

Shalini Padmanabhan, PhD, MJFF's senior vice president and head of translational research, also expressed her enthusiasm for this partnership. She stated that the foundation remains committed to their mission of finding better treatments and a cure for Parkinson's disease. By de-risking industry investment through open-science policies and collaboration with experts, including Seal Rock Therapeutics, MJFF hopes to advance LRRK2 drug development and bring new therapies to patients faster.

The addition of Seal Rock Therapeutics to the LITE program is a significant step towards finding a cure for Parkinson's disease. With their innovative LASC inhibitors and the support of MJFF, they are poised to make a meaningful impact in the lives of those living with this debilitating disease.

---

Show All News | Report Violation